Do you know the top cybersecurity attacks hiding in the cyber shadows.
23 Oct 2023, 10:55
Do you know the top cybersecurity attacks hiding in the cyber shadows? šØ Learn about the 5 common attacks that put your data at risk and how to protect against them āļø š Learn more about cyber awareness:
Same news in other sources
2
23 Oct 2023, 11:09
Triall Insights š
According to the IQVIA Institute, over 960 next-generation biotherapeutics are currently in development (Phase I through regulatory submission).
These include cell therapies, gene therapies, gene editing, nucleotide and RNA interference, mRNA therapies, and RNA or DNA vaccines.
More than 40% of these next-generation biotherapeutics in development focus on oncology, bringing great promise for cancer treatment.
Source:
š£ļø Help us spread the news:
#blockchainforhealth #TRL
Triall Insights.
Triall Insights š
According to the IQVIA Institute, over 960 next-generation biotherapeutics are currently in development (Phase I through regulatory submission).
These include cell therapies, gene therapies, gene editing, nucleotide and RNA interference, mRNA therapies, and RNA or DNA vaccines.
More than 40% of these next-generation biotherapeutics in development focus on oncology, bringing great promise for cancer treatment.
Source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2023
š£ļø Help us spread the news:
https://x.com/triallofficial/status/1716411121383473439?s=20
#blockchainforhealth #TRL
23 Oct 2023, 11:09
Triall Insights š
According to the IQVIA Institute, over 960 next-generation biotherapeutics are currently in development (Phase I through regulatory submission).
These include cell therapies, gene therapies, gene editing, nucleotide and RNA interference, mRNA therapies, and RNA or DNA vaccines.
More than 40% of these next-generation biotherapeutics in development focus on oncology, bringing great promise for cancer treatment.
Source:
š£ļø Help us spread the news:
#blockchainforhealth #TRL
Triall Insights.
Triall Insights š
According to the IQVIA Institute, over 960 next-generation biotherapeutics are currently in development (Phase I through regulatory submission).
These include cell therapies, gene therapies, gene editing, nucleotide and RNA interference, mRNA therapies, and RNA or DNA vaccines.
More than 40% of these next-generation biotherapeutics in development focus on oncology, bringing great promise for cancer treatment.
Source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2023
š£ļø Help us spread the news:
https://x.com/triallofficial/status/1716411121383473439?s=20
#blockchainforhealth #TRL